Welcome to our dedicated page for TriSalus Life Sciences news (Ticker: TLSI), a resource for investors and traders seeking the latest updates and insights on TriSalus Life Sciences stock.
TriSalus Life Sciences, Inc. develops oncology-focused drug-delivery technology and an investigational immunotherapy program for solid tumors. Its Pressure-Enabled Drug Delivery, or PEDD, platform is used through the TriNav Infusion System in interventional radiology procedures, including TARE and TACE, for primary liver cancer and liver metastases.
Company news centers on TriNav commercial performance, clinical and preclinical data for PEDD, studies in liver tumors, research involving nelitolimod, and presentations to interventional radiology audiences. Updates also include quarterly financial results, revenue guidance, capital actions, shareholder voting matters and governance changes tied to the company’s oncology technology strategy.
TriSalus Life Sciences (Nasdaq: TLSI) reported Q1 2026 revenue of $8.9 million, down 2.9% year over year, with gross margin improving to 86.2%. Operating loss was $8.4 million, while net income to common stockholders reached $1.5 million, driven by non-cash derivative gains.
The company raised $46 million, ending the quarter with $56.6 million in cash, and revised 2026 revenue guidance to $54–$57 million. TriSalus reported clinical and real-world data supporting its PEDD platform and progressed commercial expansion for the TriNav system.
TriSalus Life Sciences (Nasdaq: TLSI) reported real-world data on its Pressure-Enabled Drug Delivery (PEDD) technology in TACE and TARE procedures for liver cancers. In 603 PEDD vs. 16,210 non-PEDD patients, PEDD was associated with fewer complications, reduced 30-day hospitalizations, and about $7,734 per-patient charge avoidance.
Benefits included lower fatigue and lymphopenia rates, especially at high-volume PEDD centers, and higher delivered doxorubicin doses with fewer side effects, suggesting improved targeting and preserved immune function.
TriSalus Life Sciences (Nasdaq: TLSI) initiated patient enrollment for the PREDICTT trial on May 4, 2026, an investigator-led prospective study at UT MD Anderson assessing its TriNav Infusion System and Pressure-Enabled Drug Delivery (PEDD) with Y90 radioembolization in liver tumors.
The single-arm study will enroll approximately 20 adults with unresectable primary or metastatic liver tumors to measure CT-based tumor-to-normal liver ratios, correlate imaging with tumor dose and microsphere distribution, and evaluate safety.
TriSalus Life Sciences (Nasdaq: TLSI) will host a conference call and webcast on Tuesday, May 12, 2026 at 4:30 PM ET to discuss first quarter 2026 financial results for the quarter ended March 31, 2026. A press release with results will be issued before the call.
Dial-in registration is required; webcast and replay will be available on the company investor relations website.
TriSalus Life Sciences (Nasdaq: TLSI) will present new clinical and preclinical data at the SIR 2026 Annual Scientific Meeting April 11–15, 2026 in Toronto. Presentations on April 13–14 showcase the Pressure Enabled Drug Delivery™ (PEDD™) platform across liver, pancreatic and uterine applications.
The company highlighted investigator and preclinical work and noted nearing completion of multiple Phase 1 data sets and upcoming partnership discussions.
TriSalus Life Sciences (Nasdaq: TLSI) appointed Richard Marshall, M.D., as Chief Medical Officer, effective June 29, 2026. Dr. Marshall transitions from Medical Director (since January 2025) and will lead medical strategy, clinical development, evidence generation and broader strategic initiatives for the company’s PEDD platform and TriNav product suite.
The appointment signals continued leadership strengthening as TriSalus pursues clinical and economic advantages for its pressure-enabled drug delivery approach across solid tumors.
TriSalus Life Sciences (Nasdaq: TLSI) published preclinical data showing that Pressure-Enabled Drug Delivery (PEDD) with the TriNav® Infusion System improved intratumoral distribution and immune activation of nelitolimod in liver tumor models.
Key findings include greater tumor distribution versus microcatheter delivery, reduced myeloid-derived suppressor cells, increased CD8+ T cell infiltration, and reduced tumor growth in murine metastasis models.
TriSalus (Nasdaq: TLSI) reported strong commercial growth in Q4 2025 with $13.2M revenue (+60% y/y) and full-year $45.2M revenue (+53% y/y). The company raised $46M gross proceeds in a public offering, improved adjusted EBITDA, and reaffirmed 2026 revenue guidance of $60–62M.
Management cited product launches, expanded TriNav adoption, and planned commercial investments to support 2026 growth and broader PEDD platform adoption.
TriSalus Life Sciences (Nasdaq: TLSI) will host a conference call and webcast on Thursday, March 5, 2026 at 4:30 PM Eastern to discuss financial results for the quarter ended December 31, 2025. A press release with results will be issued before the call.
Participants can register for phone access and the webcast; a replay will be available on the investor relations website after the event.
TriSalus Life Sciences (Nasdaq: TLSI) priced an underwritten public offering of 9,756,100 common shares at $4.10 per share, with gross proceeds of approximately $40.0 million.
The company granted the underwriter a 30-day option to purchase up to 1,463,415 additional shares (15%). The offering is expected to close on or about February 23, 2026, subject to customary closing conditions.